NCT04345913 2026-03-18
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
21 trialsNCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07007559 2026-02-03
ASPEN-09
ALX Oncology Inc.
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
NCT00365157 2025-07-11
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05041101 2025-06-13
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT06202261 2024-03-12
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT01126736 2023-06-22
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Eisai Inc.
Phase 1/2 Completed
NCT05335473 2023-04-06
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03245450 2022-06-28
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02513472 2022-05-05
ENHANCE-1
Eisai Inc.
Phase 1/2 Completed
NCT01126749 2022-02-28
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT01554371 2021-02-03
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
University of California, San Francisco
Phase 1/2 Completed
NCT01323530 2021-01-11
A Confirmation Study of Eribulin in Combination With Capecitabine
Eisai Inc.
Phase 1/2 Completed
NCT01596751 2020-07-17
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT02753595 2020-07-13
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Eisai Inc.
Phase 1/2 Terminated
NCT02723877 2019-03-22
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
PIQUR Therapeutics AG
Phase 1/2 Completed
NCT01388647 2015-08-28
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Vector Oncology
Phase 1/2 Terminated
NCT02396433 2015-08-25
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
The University of Texas Health Science Center at San Antonio
Phase 1/2 Withdrawn